Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi(TM) (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Stock Information for Odonate Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Odonate Therapeutics Inc.

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025
Journey Medical Corporation Reports Combined Emrosi(TM) (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference
Journey Medical Corporation to Participate in October 2025 Investor Conferences
Journey Medical Corporation to Participate in September 2025 Investor Conferences
Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
Journey Medical Corporation to Present at the Emerging Growth Conference
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.